ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease or type 2 diabetes mellitus, accompanied by evidence of damage to the target organs. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.